Predictors of antipsychotic dose changes in the CATIE schizophrenia trial

about

Candidate gene analysis of pharmacodynamic targets for antipsychotic dosage.Mortality Risk of Antipsychotic Dose and Duration in Nursing Home Residents with Chronic or Acute Indications.Does a history of suicide attempt predict higher antipsychotic dosage in schizophrenia?

P2860

Q38919396-892D3EBD-4C48-41D7-BFC4-C2BF2F637A04 Q39776353-8BD71727-43C5-4F88-AB98-0605BEC58CA9 Q45255322-65E97FDF-A8F9-46DF-80F6-61721750192C

P2860

Predictors of antipsychotic dose changes in the CATIE schizophrenia trial

Item

http://www.wikidata.org/entity/Q37212114

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 20 April 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Predictors of antipsychotic dose changes in the CATIE schizophrenia trial

@en

Predictors of antipsychotic dose changes in the CATIE schizophrenia trial.

@nl

type

Item

label

Predictors of antipsychotic dose changes in the CATIE schizophrenia trial

@en

Predictors of antipsychotic dose changes in the CATIE schizophrenia trial.

@nl

prefLabel

Predictors of antipsychotic dose changes in the CATIE schizophrenia trial

@en

Predictors of antipsychotic dose changes in the CATIE schizophrenia trial.

@nl

P1476

Predictors of antipsychotic dose changes in the CATIE schizophrenia trial

@en

P2093

Eric Hermes

http://www.w3.org/2001/XMLSchema#string

P2860

A rating scale for drug-induced akathisia

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

The positive and negative syndrome scale (PANSS) for schizophrenia

Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study.

Measurement-based care for refractory depression: a clinical decision support model for clinical research and practice.

[Iatrogenic psychiatric-like symptoms recognition].

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.

Reasons and outcomes of olanzapine dose adjustments in the outpatient treatment of schizophrenia.

Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial.

Flexible-dose clinical trials: predictors and outcomes of antipsychotic dose adjustments.

P304

1-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.PSYCHRES.2012.03.009

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

199

http://www.w3.org/2001/XMLSchema#string

P50

Robert A. Rosenheck

P577

2012-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22521233

http://www.w3.org/2001/XMLSchema#string

P921

schizophrenia

P932

3789240

http://www.w3.org/2001/XMLSchema#string

Predictors of antipsychotic dose changes in the CATIE schizophrenia trial

about

P2860

P2860

Predictors of antipsychotic dose changes in the CATIE schizophrenia trial

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932